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Thyrot;opin releasing hormone (TRH) and its receptors are present in th~ car~iovascul~ nuclei ofthe brain as ~ell as in ~he 
intermediolateral cell column of spinal cord. Anatomical, neurophysiological, funchonal and pharmacological stud1es 
suggest that TRH is a neurotransmitter/neuromodulator in the centrat nervous system. Administration of TRH to experi-
mental animals or human subjects induces pressor and tachycardic responses and increases plasma Ievels of catechola-
mines. These effects are likely tobe mediated by a central nervous system activation of the sympathoadrenomedullary 
system with no involvement of vasopressin or renin-angiotensm system. ln the conscious rat, the TR~-induced pressor 
response is accompanied by an increment in cardiac output and a distinct change in organ blood flow, a hmdquarter skeletal 
muscle vasodilation accompanied bv renal and mesenteric vasoconstriction. The rote ofTRH in hypertension has not been 
studied. However, the extremely potent pressor and vasoconstrictor properties of TRH makes this tripeptide a candidate 
for neurotransmitters/modulators involved in the development and/or maintenance ofhypertension. The role ofTRH in the 
therapy of shock is at present controversial. Though preliminary experimental work raised hopes and expectations for 
therapeutic usage of TRH in shock and trauma, the more recent studies have shown no effect or a detrimental effect for 
TRH in some experimental shock states. 
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THYROTROPIN releasing hormone (TRH, 1-pyrogluta-
myl-1-histidyl-1-prolinamide) was the first hypothalamic 
releasing factor to be isolated, chemically characterized 
and synthesized [43]. In addition to its neuroendocrine ef-
fects (TSH, prolactin, growth hormone release), this 
tripeptide has centrat nervous actions which are totally unre-
lated to its effect on the hypothalamopituitary axis (for re-
view see [29,38]). The presence of TRH immunoreactivity 
and TRH receptors in brain areas related to the cardiores-
piratory control, together with the extremely potent pressor 
and tachycardic actions of exogenously administered TRH 
suggest that this peptide might have a role in modulating the 
brain regulation of blood pressure and respiration. This re-
view aims to summarize the sturlies on TRH in the centrat 
nervous system with special emphasis on the cardiovascular 
pharmacology of this peptide. 
TRH SYSTEM IN THE DRAIN 
TRH immunoreactivity is unevenly distributed through-
out the centrat nervous system (see [42,43]). Although the 
highest local concentrations are found in the hypothalamus 
(especially in the median eminence, periventricuJar arcuate, 
dorsomedial and ventromedial nuclei), more than 70% of the 
total CNS TRH is located in extrahypothalamic areas. Out-
side the hypothalamus high locallevels of TRH are found in 
the lateral nucleus of the septum in the limbic area and in the 
nucleus of the solitary tract (NTS) in the medulla oblongata; 
moderate to low Ievels in preoptic nuclei, midbrain and cor-
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texandin the spinal cord [42]. Specific binding sites for TRH 
in the rat brain were first characterized by Burt and Snyder 
[ 6]. Since then, TRH receptors have been found in the brain 
and spinal cord of many vertebrales including man [35, 36, 
45, 49, 54]. Autoradiographie mapping of the receptor sites 
has revealed a somewhat different distribution of the TRH 
receptors from that of the peptide TRH. However, the ex-
tensive distribution of TRH receptors in the CNS provides 
an explanation for a variety of centrat nervous actions ob-
served when TRH is administered into the brain [48]. 
In the rat brain, TRH arises from the post-translational 
cleavage of a large precursor protein [31 ,46]. Brain synapto-
somes are rieb in immunoreactive TRH and im-
munocytochemically TRH has been shown to be present in 
nerve endings [42]. Moreover, TRH is released in vitro by 
various stimuJi to be retaken up by the rat bram shces in vitro 
[43]. 
The findings that TRH is co-localized with substance P 
and serotonin in some brain nuclei and TRH is able to in-
crease the number of serotonin receptors [20,48] further 
suggest a neuromodulatorrote for TRH in the CNS. For 
more detailed review on the neurochemistry of TRH see the 
recent reviews of Prasad [43] and Sharif (48]. 
CARDIOVASCULAR PHARMACOLOGY OF TRH 
TRH induces a strong pressor response in both experi-
mental animals [3, 10, 14, 27, 32, 52] andin man [1, 4, 39, 55]. 
In animals the TRH-induced hypertensive effect is accom-
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panied with a moderate to strong tachycardia, while in hu-
mans it does not seem to affect heart rate. In both 
anesthetized [32] and conscious [50] rats intracerebroven-
tricularly (ICV) administered TRH is one of the most potent 
pressor agents known, producing significant increments of 
mean arterial pressure at subnanomolar doses. A prolonged 
pressor effect can also be induced by using TRH-analogs 
such as the CG3703 compound [51] which are highly resis-
tant to TRH metabolizing enzymes [ 19 ,38]. Furthermore, the 
apparent Iack of tachyphylaxis to the cardiovascular effects 
of TRH [32,50] further suggests that this tripeptide might be 
involved in the pathophysiology of hypertension. However. 
the potential roJe of TRH in various experimental hyperten-
sive models must still be elucidated. 
Sire ofAction 
The cardiovascular effects of TRH are likely to be due to 
an action of the agent on the centrat nervous system, since 
the doses needed to elicit rises of mean arterial pressure and 
heart rate after systemic injections are a thousandfold higher 
than the doses used ICV or for injections into discrete brain 
nuclei (12, 14, 32, 50]. Moreover, in anesthetized rabbits, 
transections in the cervical spinal cord abolished the pressor 
response to ICV administered TRH while spinal transections 
below T 1 had no effect on the TRH response [27]. The rever-
sal of leukotriene D4 induced hypotension is also totally 
abolished in the pithed rat in which the entire CNS and car-
diac reflexes are eliminated [ 15]. 
A few studies to date have so far tried to localize the 
pressor and tachycardic effects of TRH in the brain. Feuer-
stein and coworkers [14] injected nanomolar doses of TRH 
or its histidyl analogs [ 16) into the nucleus preopticus 
medialis (POM) of conscious rats. The magnitude of the in-
crements in mean arterial pressure and heart rate after the 
POM injections were, however, at the same range as the 
effect produced by ICV injections of the same doses of TRH 
[32,50]. However, the increase in heart rate was somewhat 
high er. Microinjections of picomolar doses of TRH into var-
ious hypothalamic nuclei in halothane anesthetized rats also 
elicited slight increases of blood pressure and heart rate 
without any changes in respiration or body temperature [9]. 
Immunohistochemical visualization of TRH containing 
nerve cells and fibers as well as a high density of TRH recep-
tors in the hypothalamus [36, 42, 45] further suggest that 
these brain areas might be important for the cardiovascular 
actions of TRH. Moreover, endogenous TRH might have a 
rote in the hypothalamic regulation of the cardiovascular sys-
tem. In contrast to these findings, it was recently reported 
that the pressor response to TRH can be elicited also with 
injections into the fourth ventricle [41]. Moreover, occlusion 
of the cerebral aqueduct attenuated the increment of blood 
pressure produced by ICV administered TRH, while the 
tachycardia induced by TRH was unaffected by this proce-
dure [41]. These findings suggest that the pressor response to 
TRH can, at least in part, be due to an activation of brain 
areas within the reach of the fourth ventricle. The nucleus of 
the solitary tract has been shown to have a high content of 
TRH immunoreactivity [42] and also TRH receptors [36]. 
However, microinjections of nanomolar doses of TRH into 
the NTS of the pentobarbitone anesthetized rat elicited, in-
stead of a pressor effect, a moderate depressor response on 
blood pressure which was accompanied by a slight tachy-
cardia [14]. The NTS has been indicated to be a sensitive 
brain site for the respiratory stimulant action (tachypnea, 
increase in ventilatory volume) in the rat (8,22]. 
SlREN 
Hemodynamic Mechanism Involvecl in the Cardim•a.\'Citlar 
Actions l~{ TRH 
Although the pressor and tachycardic effects of TRH 
have been repeatedly documented (see above), little is 
known for the hemodynamic and regional blood flow 
changes after TRH administration. By using the thermodilu-
tion technique we found that the pressor and tachycardic 
effects ofboth ICV and systemically administered TRH were 
accompanied by a simultaneous increase in cardiac output, 
while TRH had no effect on total peripheral resistance (Sin~n 
et al.. manuscript in preparation). The sarne pattern of 
hemodynamic changes was observed also after systemic in-
jection of a potent TRH analog, CG3703 [ 19), in conscious 
rats [5 I]. In man, TRH injected intravenously seems to 
produce opposite changes in gross hemodynamic variables 
and the pressor response in humans is more likely to be due 
to an increase in resistance than to an incrernent of cardiac 
output [55}. By using the ultrasound directional pulsed Dop-
pler method we have also shown [50] that ICV administra-
tion of low doses (0.8-80 nmol/kg) of TRH produced a dis-
tinct pattern of regional blood flow changes in the conscious 
rat: the blood flow to skeletal muscles significantly increased 
and vascular resistance decreased after TRH injections, with 
opposite changes in the renal (and to a lesser degree in the 
mesenteric) blood flow and vascular resistance. The differ-
ential pattern of blood tlow changes in these vascular beds 
might explain the Iack of effect of TRH on total peripheral 
resistance. These findings also underline the importance in 
studying the effect of TRH (and other peptides) on regional 
blood flow and vascular resistance; the potent vasoconstric-
tor effect of TRH on the renal vasculature might not only 
play a roJe in the regulation of renal hemodynamics but 
also indirectly in the control of systemic blood pressure. 
The Role ~~r thc Autonomie Nerl'lws Sy.\·tcm 
The cardiovascular effects of TRH have been related to 
an activation of sympathetic outflow, since these changes 
are accompanied by increases in plasma catecholamines in 
both animals [5, 14] and man [39). Although measuring 
plasma catecholamines might not be a good index for the 
sympathetic nerve activity, these suggestions are further 
supported by the findings that the pressor effect of ICV ad-
ministered TRH in rat endotoxic shock is abolished by ad-
renal demedullation [26]. In conscious adrenal demedullated 
rats, the tachycardia elicited by TRH injections into the 
POM was also inhibited and the pressor response partly 
attenuated by bretylium treatment [ 14]. Sturlies in progress 
in our laboratory have revealed that the increments of blood 
pressure, heart rate and cardiac index induced by TRH are 
partly attenuated in adrenal demedullated rats, and are not 
significantly effected by further treatment with bretylium. 
The renal vasoconstrictor response to TRH, on the other 
band, is reduced to 50% in adrenal demedullated animals and 
the vasodilation in skeletal muscle almost totally inhibited by 
bretylium in these rats. As compared to the other known 
vasoactive substances such as epinephrine, norepinephrine, 
angiotensin, vasopressin or platelet activating factor ((11, 13, 
51], unpublished findings of our laboratory), the pattem ofthe 
changes in blood flow in skeletal muscle, mesenteric and 
renal vascular beds by TRH mostly resembled that induced 
by norepinephrine while all the other above mentioned 
agents induced totally different changes in blood flow as that 
produced by TRH. Furthermore, direct resolving of renal 
sympathetic nerve activity in anesthetized rats revealed a 
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FIG. 1. A representable chart recording ofarteri~.pre~sure (AP) and renal sympathetic ne~ve activ_ity 
(RSN A) in the anesthetized rat after intravenous t?JectiOns ~f!H~ (0.3-10 ~J.mollkg). C~lonsondamme 
(5 mg/kg) was administered intravenously 20 mm before InJeCtton of TRH at the htghest dose (10 
JLmol/kg) was repeated. 
profound activation of nerve firing by TRH even at doses 
which did not affect the arterial pressure (Fig. 1). Both the 
hemodynarnic and neural effects of TRH were abolished by 
the ganglion blocker chlorisondarnine (Fig. 1). These data 
taken together suggest that the cardiovascular effects of 
TRH at least in part, involve an activation of the sym-path~adrenomedullary axis. Howeve~, any pharmacologic~l 
intervention to block the sympathehc or parasympathet1c 
pathways (hexamethonium, reserpine, phentolamine, pro-
pranolol, atropine) were not effective in inhibiting the in-
creases in blood pressure and heart rate produced by TRH 
ICV in the anesthetized rabbit [27 ,28]. Thus, the involve-
ment of sympathetic nerves and adrenal medulla in the car-
diovascular actions of TRH is at present clearly controver-
sial. Although an incomplete blockade of adrenergic nerves 
andlor receptors by sympathetic blocking agents might ex-
plain the Iack of inhibition of TRH effects in the studies cited 
above a nonadrenergic component of action may also be propo~ed. This view is further supported by the recent clini-
cal findings by Zaloga and coworkers [55] that the pressor 
response to TRH in humans was not accompanied by any 
increments of plasma catecholamines. The importance of 
vasopressin and renin-angiotensin system in the TRH-
induced cardiovascular changes is discussed in the next 
chapter. Briefly, neither of these systems seem to be in-
volved. It is therefore possible that neurotransmitters other 
than norepinephrine which are released by sympathetic ac-
tivation contribute to the cardiovascular responses to TRH. 
Possible candidates for such neurotransmitters might include 
neuropeptide Y (NPY) or opioid peptides which are col-
ocalized and coreleased from sympathetic nerve endings and 
adrenal medulla with norepinephrine [18,40]. Systemic ad-
ministration of NPY to rats results in vasoconstrictor and 
pressor responses similar to TRH [40], while the effects of 
various opioid peptides are more complex [18]. However, 
the importance of these mediators in the cardiovascular ac-
tion of TRH must still be elucidated. Furthermore, direct 
recording of sympathetic nerve traffic to various organs fol-
lowing TRH administration would further clarify the rote of 
the sympathoadrenomedullary system in the vasoconstric-
tor/vasodilator actions of TRH. 
Other Possible Mediators of the TRH Effect 
Plasmavasopressin Ievels have been reported to increase 
after systemic or centrat administration of TRH in rabbits 
[28,53], while in dogs TRH does not have any effect on 
plasma vasopressin [30]. However, the increment in plasma 
vasopressin seems to be unrelated to its cardiovascular ac-
tions, since hexamethonium blocked the effect of TRH on 
vasopressin but had no influence to its concomitant pressor 
response [28]. Moreover, repeated administrations of vaso-
pressin to anesthetized rabbits (to induce tachyphylaxis) had 
no effect on the TRH-induced hypertensive response [28]. 
Studies in progress in our laboratory have shown that in the 
conscious rat systemic administration of a high dose of TRH 
(2 mg/kg) induced a statistically significant rise in plasma 
vasopressin, but the magnitude of this increase was below 
the Ievels at which vasopressin can induce changes in blood 
pressure (7]. Pretreatment of urethane-anesthetized rats with 
a vasopressin antagonist failed to block the cardiovascular 
actions of ICV administered TRH [37]. The involvement of 
the other pressor system, the renin-angiotensin system, in the 
hypertensive effect of TRH seems also likely, since TRH has 
no effect on plasma renin activity in either the conscious rat 
(own unpublished observations) or in man [39]. 
TRH inShock 
Holaday and coworkers [24,25] were the first to suggest 
that TRH might have a beneficial effect in cardiovascular 
shock. They found that a systemic injection of a high dose of 
TRH (2 mg/k.g) reversed the hypotension in rat hemorrhagic 
[24] and endotoxic shock [25]. Studies in our laboratory have 
shown that TRH, administered both systemically and di-
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rectly into the brain ventricles, reversed also the hypoten-
sion indu~ed by leukotriene 0 4 , platelet activating factor, 
soybean hpoxygenase or antigen induced anaphylaxis in the 
conscious guinea pig [17, 33, 34]. In cantrast to its weil 
documented pressor response in cardiovascular shock the 
beneficial effect of TRH in various shock states seems {o be 
controversial. Holaday et al. [25] reported increased short-
term survival (2 hours after the shock) by TRH in endotoxic 
shock but bad no data on the survival in rat hemorrhagic 
shock. Some preliminary studies on cynomulgus monkeys 
[21,44], on the other band, suggest a beneficial effect ofTRH 
on survival in hemorrhagic shock but not in the endotoxic 
shock. In mice anaphylactic shock TRH significantly re-
duced mortality which was probably mediated by a central 
nervaus stimulation of the sympathetic outflow [2]. Our re-
cent results [51] clearly showed that TRH or its long-acting 
analogue CG3703 (see above) increased mortality in con-
scious rats exposed to hemorrhage. In addition to the re-
duced survival, we also found that the pressor effect induced 
by CG3703 in rat hypovolemic hypotension was due to a 
sharp increase in the total peripheral resistance, while the 
cardiac output tended to be reduced by the treatment. 
M~reover, the regional blood flow in skeletal muscle, mesen-
tenc and renal vascular beds was significantly impaired by 
the treatment. These results may thus provide explanation 
for the Iack of beneficial effect of TRH; reduced blood flow 
to vital argans tagether with the reduction of cardiac output. 
The Iack of any beneficial effect of TRH on either cardiovas-
cular parameters or survival in cat or rabbit hemorrhagic 
shock or in rat traumatic shock was recently confirmed by 
others [23,47]. 
Thus, the beneficial effect of TRH in shock seems tobe 
dependent on the shock modelas weil as the species studied. 
TRH and its stable analogs may prove to be beneficial in 
anaphylactic shock whereas in hypovolemic shock, TRH 
exacerbates the shock and causes a sustained reduction of 
blood flow in vital organs. 
SIREN 
SUMMARY 
TRH immunoreactivity and highly specific binding sites 
for TRH are found in neuronal cell bodies and tibers 
throughout the vertebrale centrat nervous system. The neu-
romodulator role for TRH is further suggested by the facts 
that in the brain this tripeptide arises from a large precursor 
protein and has its own releasing, uptake and degradation 
mechanisms. Administration of TRH to animals or man in-
duces a potent pressor response and increases plasma cate-
cholamine Ievels probably mainly by a centrat nervous ac-
tivation of sympathoadrenomedullary axis. In the rat, the 
TRH-induced pressor response is accompanied by increases 
in heart rate and cardiac output and skeletal muscle blood 
flow, while in renal and mesenteric vasculature it produces 
vasoconstriction. The cardiovascular actions of TRH seem 
not to involve other known pressor systems such as the 
renin-angiotensin system or vasopressin release. The roJe of 
TRH in different hypertension models has not been studied. 
However, the extremely potent pressor effect oftbis peptide 
makes TRH a candidate for neurotransmitters or modulators 
involved in the development and/or maintenance of hyper-
tension. 
The roJe of TRH in the therapy of a variety of shock states 
and trauma is at present controversial. Although preliminary 
experimental work raised hopes and expectations for 
therapeutic usage of TRH in shock and trauma. the more 
recent studies have shown no effect or a detrimentaJ effect 
for TRH in somc experimental shock states. 
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